Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised, Double-Blind, Placebo-Controlled Study to Investigate GNbAC1 in Patients With Onset of Type 1 Diabetes Within 4 Years

Trial Profile

Randomised, Double-Blind, Placebo-Controlled Study to Investigate GNbAC1 in Patients With Onset of Type 1 Diabetes Within 4 Years

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Dec 2018

At a glance

  • Drugs Temelimab (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms RAINBOW-T1D
  • Sponsors GeNeuro Australia
  • Most Recent Events

    • 20 Dec 2018 According to a GeNeuro media release, final 12- month results from this study is anticipated in the second quarter of 2019.
    • 24 Oct 2018 According to a GeNeuro media release, the study met its primary endpoint of safety in this new patient population.
    • 20 Sep 2018 According to a GeNeuro media release, final visit of the last patient is expected by the end of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top